Member Info for Wolfbag2

ATrades - 1666 posts - you really should know this stuff !!!

https://investinganswers.com/dictionary/d/dividend-record-date

https://www.dividenddata.co.uk/ex-dividend-date-search.py?searchTerm=gkp

Perhaps not MBU - think the CLN route is more likely - ACAM Gp Ltd (owned by Hedge Fund Manager) - maybe they just took their profits ?!
Terms of the Convertible Loan Notes
On 14 December 2021 the Company entered into an unsecured convertible loan note agreement with the Lender for a
total subscription of $6,000,000 Convertible Loan Notes. The Convertible Loan Notes have a term of two years and
attract interest at a rate of 15% per annum, which is payable monthly in arrears commencing on 31 January 2022.
Interest will be payable via the issuance of additional Convertible Loan Notes as payment in kind. The Convertible Loan
Notes are unsecured. The Notes shall be issued by the Company in multiples of $500,000.
The Notes shall be convertible into new ordinary shares of the Company ("Ordinary Shares") at the price of 28 pence per
new Ordinary Share (the "Conversion Price"), a discount of 11.1% to the closing middle-market price of an Ordinary
Share on 6 December 2021, when a non-binding term sheet for the Convertible Loan Notes was agreed. The discount
based on the closing middle-market share price of an Ordinary Share on 14 December 2021 was 13.8%. The Notes shall
be convertible, in part or in full, at the option of the Lender from the date of issuance until five business days prior to the
final repayment date, being 31 December 2023. Until conversion, the Notes do not give the Lender voting rights over the
ordinary shares or dividend rights.
From 1 July 2022 the Company may offer to redeem any Notes not converted at 125% of par in cash. The Lender will
have a period of five business days to respond to an offer to redeem with a conversion notice which would render the
offer to redeem null and void and such Notes would convert into new Ordinary Shares at the Conversion Price.
To the extent the Convertible Loan Notes are not repaid, redeemed or converted, on 31 December 2022, 50% of the
balance of the Notes shall be redeemed at the principal amounts plus accrued interest in cash. The remainder shall be
redeemed on 31 December 2023

gonna be record volumes traded today - no RNS (price monitoring extensions) so far - no news - maybe MBU selling down their holding ?

$2.5 million sitting idle doesn't make sense to me unless failing to meet contractual obligations out-weigh the cost - then again- I don't have $2.5 million sitting idle . . . . . .

cos there's an anticipated surge when the yanks actually wake up and turn on their computers to get busy with their day

u mean they can buy anytime the market is OPEN in the UK

14:30 methinkx Magic

Ghia - curious on this one too - but I dug this out (out of date I know but may give some clue as theres evidently some comparables)

https://www.hardmanandco.com/wp-content/uploads/2018/12/Genedrive-FY18-11-December-2018.pdf

Gross margin: During the build-up phase, gross margins for the Genedrive
HCV-ID test and Genedrive unit are expected to be stable, at around 33%-50%,
compared with the higher gross margins reported.

Can't blame the short-termers really - 50% over a few days is no bad return

revenue for last 5 years - never previously exceeded £2.5million -
may actually be profit making by 2023

Id double check Bolton - last time I looked a "pain in the ass" wasn't on the list of recognised covid symptoms ;)

What is the Genedrive®?
Genedrive® is a portable, rapid, molecular diagnostics device. It can be easily operated under a range of near patient testing situations with limited requirement for ancillary equipment or test materials such as point of care decentralised laboratories and field-deployment. It is intended for in vitro diagnostic detection and discrimination of nucleic acid signatures for a variety of applications, target types and sample matrices. The instrument provides rapid nucleic acid amplification, detection and result reporting without the need for data interpretation.

Reads to me like once NHS are using even a single device that further assays can be flogged to them for a whole range of genetic linked afflictions (whether existing or still in pipeline) at £80 a pop (or more ?) - is this really as MEGA as I read it ?

Surely Jenni - it's a "hedged" option - I think they have initiated it to "see what happens" and only actually exercise that option if reaches that point where it appears to be in the best interests of the company and (err.... and the shareholders)

https://www.england.nhs.uk/2022/04/nhs-develops-world-first-bedside-genetic-test-to-prevent-babies-going-deaf/
https://www.nice.org.uk/advice/mib290/chapter/The-technology

I'm GENUINELY in full support of the RNS issued - The company is well placed both geographically and financially to offer such aid as they see fit in this time of crisis and to hell with the financial consequences to shareholders - it is right and proper for them to do so - Well done to the board of FXPO

KIGHT - simple google search comes up with attached if it helps . . . . . COMPUTER RISK MANAGEMENT LIMITED (02783851) - based Manchester/Hale area

https://find-and-update.company-information.service.gov.uk/officers/YkzNMpkD8tZqdmgDo79sMDEUQdo/appointments

Spot on Jenni - more or less exactly as I see it !

My somewhat simple take as it stands

ordinary shares will be converted into preference shares by way of a bonus issue (at what rate is anybody's guess at this time but I'm guessing (and hoping) somewhere in the range one for three to one for six)
the preference shares are simply a surety against debt - again the market will ultimately value something approximating their worth, it'll be personal choice whether or not you trade them if and when a market actually opens up for them.

Apart from the delisting and conversion - it's all been "hedged" into a put option which may or may not be exercised (depending on the Ukraine and sanction situations) at some time in the future

The whole thing being put in place to mitigate exposure to sanctions against Russia and the uncertainty of the Rouble exchange rate and even their ability to get revenue out of Russia

Nobody knows what the outcome in Ukraine is going to be and Raven are simply trying to "protect" their assets for the "benefit of their employees and stakeholders" (take that as you will !!!!). I think they are actually kicking the can down the road a little bit as I'm clueless as to how long any "required regulatory and other approvals" are likely to take - if Ukraine is "all over" or massively improved by the time the approvals have come through then the nature of the "put" option means they can re-assess the whole damned mess !!! (which is not, let us remember, of their own making !!)

Lets face it - there's nothing we can do at the moment - can't even sell - so it's back to the bottom drawer for these little bunnies and hope for the best !!!)

GLTALTH !!!

https://www.rrhcyprus.com/about/

looks not dissimilar from

https://www.theravenpropertygroup.com

@BigK - Bens Creek is available on Trading212 - £1 minimum trade (fractional shares too !)

"The ability of the Company to continue to access the funds of its Russian subsidiaries and whether those funds can be converted to the correct currency at a commercial exchange rate is the greatest uncertainty at this time."

Hmmmm says it all really - can't see why it can't continue to earn loadsa dosh - problem is that we are probably screwed unless you want it in roubles . . . . . definitely a share to pop in a back drawer and forget for a while (IMHO of course)